1. Home
  2. Analysis
  3. Lovaza
  4. Alkeran

Lovaza and Alkeran drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lovaza and Alkeran. Common interactions include osteoporosis among females and anxiety among males.

The phase IV clinical study analyzes what interactions people who take Lovaza and Alkeran have. It is created by eHealthMe based on reports of 22 people who take Lovaza and Alkeran from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 03, 2023

22 people who take Lovaza and Alkeran together, and have interactions are studied.

What is Lovaza?

Lovaza has active ingredients of omega-3-acid ethyl esters. It is often used in high blood cholesterol. eHealthMe is studying from 16,913 Lovaza users for its effectiveness, alternative drugs and more.

What is Alkeran?

Alkeran has active ingredients of melphalan. eHealthMe is studying from 5,429 Alkeran users for its effectiveness, alternative drugs and more.

Number of Lovaza and Alkeran reports submitted per year:

Lovaza and Alkeran drug interactions.

Common Lovaza and Alkeran drug interactions by gender *:

female:

  1. Osteoporosis
  2. Spinal compression fracture
  3. Spinal fracture
  4. Amyloidosis
  5. Ankle fracture
  6. Blood potassium decreased
  7. Blood pressure increased
  8. Cardiac arrest
  9. Cardiac disorder
  10. Cardiac failure congestive

male:

  1. Anxiety
  2. Osteonecrosis of jaw
  3. Pneumonia
  4. Thrombocytopenia
  5. Arthralgia
  6. Arthropathy
  7. Discomfort
  8. Emotional distress
  9. Haematochezia
  10. Inguinal hernia

Common Lovaza and Alkeran drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Back pain
  2. Nerve root compression
  3. Osteoporosis
  4. Spinal compression fracture
  5. Spinal fracture
  6. Amyloidosis
  7. Ankle fracture
  8. Blood potassium decreased
  9. Blood pressure increased
  10. Cardiac arrest

50-59:

  1. Myofascial pain syndrome
  2. Osteonecrosis of jaw
  3. Pain
  4. Pleural fibrosis
  5. Post laminectomy syndrome
  6. Sciatica
  7. Spondylitis
  8. Anhedonia
  9. Decreased appetite
  10. Deformity

60+:

  1. Pancytopenia
  2. Renal failure chronic
  3. Cardiac failure congestive
  4. Cardiomegaly
  5. Chronic obstructive pulmonary disease
  6. Death
  7. Device related infection
  8. Disability
  9. Gastritis
  10. Hyperkalaemia

Common conditions people have *:

  1. Multiple Myeloma (cancer of the plasma cells): 14 people, 63.64%

* Approximation only. Some reports may have incomplete information.

Do you take Lovaza and Alkeran?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Lovaza and Alkeran:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Lovaza side effects:

Browse all side effects of Lovaza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Alkeran side effects:

Browse all side effects of Alkeran:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Lovaza interactions:

Browse all interactions between Lovaza and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Alkeran interactions:

Browse all interactions between Alkeran and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on omega-3-acid ethyl esters and melphalan (the active ingredients of Lovaza and Alkeran, respectively), and Lovaza and Alkeran (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Lovaza and Alkeran.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.